Induction of Ovulation with (CLOMIMED 50) Clomiphene Citrate

The most common causes of reproductive failure in subfertile and infertile couples are ovulatory dysfunction. Since the very first clinical trial was published in 1961, (CLOMIMED 50) Clomiphene Citrate remains the most commonly prescribed ovulation-inducing medication and is the front-line therapy in the largest majority of anovulatory infertile women. Its use quickly expanded to other empiric indications, such as luteal phase defect and the enhancement of fecundity in case of unexplained infertility. Although a lot of other solutions appeared in recent years, (CLOMIMED 50) Clomiphene Citrate is still widely used.

Initial studies of the therapeutic potential of (CLOMIMED 50) Clomiphene Citrate focused on its adverse effects on fertility in animals. In 1961, the first clinical trial for ovulation induction in women was performed. Briefly after, the second trial reported successful induction of ovulation in nearly 80% of a group of amenorrheic anovulatory women, half of whom successfully conceived during treatment. Today, despite the advent of modern immunoassays for steroid hormones, results of (CLOMIMED 50) Clomiphene Citrate treatment remained the same and have not changed. Nowadays, such advances as ultrasound technology for cycle monitoring and the introduction of commercial ovulation predictor kits (OPK) allow accurate identification of the midcycle luteinizing hormone (LH) surge. Tracking the surge in luteinizing hormone levels can help to plan intercourse and increase the chances of becoming pregnant.

Indications for treatment with (CLOMIMED 50) Clomiphene Citrate

There are three main indications for (CLOMIMED 50) Clomiphene Citrate:

• Anovulation.

There are many and varied causes of anovulation. The right treatment should be directed at correcting the underlying cause because the correct diagnosis may suggest specific treatment and many of these conditions may have longer-term health consequences. In most cases, the immediate cause of anovulation cannot be confidently defined. Following health problems may be identified: thyroid disease, pituitary tumors, eating disorders, extremes of weight loss and exercise, hyperprolactinemia, polycystic ovary syndrome, and obesity. (CLOMIMED 50) Clomiphene Citrate is the initial treatment of choice for most anovulatory or oligo-ovulatory infertile women who are euthyroid and euprolactinemic and have normal circulating levels of estrogen hormone.

• Luteal Phase Deficiency

Luteal phase deficiency has been defined as a condition in which the ovarian secretion of progesterone is not sufficient to maintain a functional secretory endometrium that supports embryo implantation and growth of early pregnancy. Given that the corpus luteum derives from the follicle that ovulates, its functional capacity is, at least in part, dependent on the quality of preovulatory follicle development. Progesterone levels are typically higher after (CLOMIMED 50) Clomiphene Citrate treatment than in spontaneous cycles, reflecting improved preovulatory follicle and corpus luteum development and/or the hormone production from more than one corpus luteum.

• Unexplained Infertility

That happens, that sometimes the reasons for infertility remains unexplained even after a careful and thorough evaluation. Treatment with (CLOMIMED 50) Clomiphene Citrate can be a good option, particularly in young couples with relatively brief duration of infertility and in those unwilling or unable to pursue more aggressive therapies involving greater costs, risks, and logistic demands. Such treatment is most effective when it is combined with properly timed intrauterine insemination (IUI), all to bring together more than the usual amount of ova and sperm at the optimal time.